You are here

P&T® Journal contents for May 2006


The authors present a study in which they sought to identify patterns of disparities in race and sex in the use of health care resources by Medicaid patients with COPD, a population composed predominantly of minorities, women, and children.
Fadia T. Shaya, PhD, MPH, Antoine C. El Khoury, PhD, Navendu D. Samant, BS, PhD Candidate, and Steven M. Scharf, MD, PhD
Meeting Highlights
Topics include therapies with atorvastatin for hypercholesterolemia and mixed dyslipidemia, aliskiren and darusentan for hypertension, perindopril for coronary artery disease, bivalirudin for acute coronary syndrome, atorvastatin for atrial fibrillation, and darbepoetin alfa and carvedilol for heart failure.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Dr. Goldenberg reviews advances in the treatment of lymphoma, including chemotherapeutic agents, monoclonal antibodies, radiolabeled products, and antisense drugs.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
A panel of experts in allergies and pulmonology discuss the appropriate use of omalizumab with respect to current asthma guidelines and review the drug’s ability to improve symptoms, reduce exacerbations, and decrease patients’ use of health care resources.
Mark J. Baumel, MD, Lawrence Du Buske, MD, Stanley J. Szefler, MD, Lanny Rosenwasser, MD, and David B. Nash, MD, MBA


David Nash, MD, MBA discusses the Canadian Coordinating Office for Health Technology Assessment, a source of information on drugs, devices, and “best practices” in Canada.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, alerts us to the confusion that can results when multiple, related errors occur simultaneously. Examples: when branded generic products are available from different manufacturers and when a drug is dispensed by its brand name and by its generic name to the same patient.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas comments on Wyeth’s petition to the FDA to stop compounding pharmacies from selling bioidentical hormones to women.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, and devices.
Drug Forecast
The authors review exenatide (Byetta) for treating diabetes.
Sweta Chawla, PharmD